High Potency APIs Market is expected to grow at a CAGR of 8.7% during the forecast period. Global High Potency APIs Market is expected to reach US$ 44.07 Bn. by 2029. The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report High potency active pharmaceutical ingredients (HPAPIs) form an integral part of new drugs which is under developing process. HPAPIs have the capability of targeting diseased cell selectively and exactly than other compounds. HPAPIs continue to be an area of interest to the pharmaceutical manufacturing industry. The share of HPAPIs in the global API market is growing very fast. Various pharmaceutical companies are recognizing the strong growth potential in the high potency APIs market. Some key players are considering spending in new high potency APIs production facilities, while others are planning the expansion of their production capacity of HPAPIs to meet the fast-growing demand. Such as, in June 2021, Lonza Company announced the expansion of high potency APIs to upsurge the product portfolio as well as offer flexibility and delivery of the number of products in the treatment of cancer patients. The report contains a detailed study of factors that will drive and restrain the growth of the high potency APIs market. As per the World Health Organization's International Agency for Research (IARC) on Cancer report published in September 2021, the cancer burden increased near 18.1 million new cases and 9.6 million deaths in 2021, worldwide. Also, 70% of deaths from cancer occur in middle and low-income economies. So, the growing number of cancer cases is expected to increase revenues for the HPAPIs market. Nearly 25% of new chemical entities are considered as potent, which can mainly be credited to the fact that about one-third of all drug candidates are oncology treatments. The largest percentage of high potency APIs is used in the formation of anti-cancer drugs. By product, the biotech segment was valued at US$ xx.22 million in 2021 and is expected to reach a value of US$ xx.14 million by 2029, with a CAGR of 21% during the forecast period. The biotech segment is expected to witness productive growth because of the technological advancements in the product segment and the high level of effectiveness of these ingredients. Biotech HPAPI mainly includes of drug molecules obtained after usage of molecular techniques like recombinant DNA technology. The outsourcing of high potency APIs manufacturing is growing in India and China because of the cost advantage. The trend of outsourcing is also rising in the Eastern European economies as the cost of manufacturing in North America and the EU is comparatively higher. North America, having a highly developed and regulated pharmaceutical industry, holds the largest market for high potency APIs with a dominating share of xx% in the global market in 2021. Cancer is the second most important cause of death, after cardiac diseases, in this region. Cancer therapy drugs have the largest share in the US$ xx.4 Bn North American high potency APIs market and show the strongest growth of any therapeutic type in the region’s pharmaceutical industry. Europe is the second-largest high potency APIs market with a share of xx%, currently standing at US$ xx.5 billion in 2021. The largest market in Europe is the U.K. with a 22% share in the regions’ high potency APIs demand, followed by Germany with 15 % and France with a 10% share. The market in Eastern European economies is fast-growing with a current share of 26%. In April 2021, Cambrex Company provider of drug substance, drug product and analytical services announced that they completed the construction of a US$24 Mn. HPAPI manufacturing facility at Charles City, IA. The new facilities will offer Flexibility to manufacturing network and scale up the projects progress. The objective of the report is to present a comprehensive analysis of the Global High Potency APIs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global High Potency APIs Market dynamics, structure by analyzing the market segments and projects the Global High Potency APIs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global High Potency APIs Market make the report investor’s guide.
Scope of the Global High Potency APIs Market: Inquire before buying
Global Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 22.61 Bn. Forecast Period 2022 to 2029 CAGR: 8.7% Market Size in 2029: US $ 44.07 Bn. Segments Covered: by Product • Biotech • Synthetic by Type • Novel • Innovative • Generic by Therapeutic Area • Oncology • Glaucoma • Hormonal by Manufacturer • Captive • Merchant Global High Potency APIs Market, By Region
• Asia Pacific • North America • Europe • South America • Middle East & AfricaKey players operating in the Global High Potency APIs Market
• Mylan, Inc. • Boehringer Ingelheim • Sanofi • AbbVie • Pfizer Inc. • Novartis International AG • Merck & Co. • Cambrex Corporation • Teva Pharmaceutical Industries Ltd. • Eli Lilly and Company • Lonza • AstraZeneca plc • Bristol-Myers Squibb • GlaxoSmithKline plcFrequently Asked Questions:
1. Which region has the largest share in Global High Potency APIs Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Global High Potency APIs Market? Ans: The Global High Potency APIs Market is growing at a CAGR of 8.7% during forecasting period 2022-2029. 3. What is scope of the Global High Potency APIs market report? Ans: Global High Potency APIs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global High Potency APIs market? Ans: The important key players in the Global High Potency APIs Market are – Mylan, Inc., Boehringer Ingelheim, Sanofi, AbbVie, Pfizer Inc., Novartis International AG, Merck & Co., Cambrex Corporation, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Lonza, AstraZeneca plc, Bristol-Myers Squibb, and GlaxoSmithKline plc 5. What is the study period of this market? Ans: The Global High Potency APIs Market is studied from 2021 to 2029.
Global High Potency APIs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global High Potency APIs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global High Potency APIs Market Analysis and Forecast 6.1. Global High Potency APIs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global High Potency APIs Market Analysis and Forecast, By Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global High Potency APIs Market Value Share Analysis, By Product 7.4. Global High Potency APIs Market Size (US$ Bn) Forecast, By Product 7.5. Global High Potency APIs Market Analysis, By Product 7.6. Global High Potency APIs Market Attractiveness Analysis, By Product 8. Global High Potency APIs Market Analysis and Forecast, By Manufacturer 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global High Potency APIs Market Value Share Analysis, By Manufacturer 8.4. Global High Potency APIs Market Size (US$ Bn) Forecast, By Manufacturer 8.5. Global High Potency APIs Market Analysis, By Manufacturer 8.6. Global High Potency APIs Market Attractiveness Analysis, By Manufacturer 9. Global High Potency APIs Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global High Potency APIs Market Value Share Analysis, By Type 9.4. Global High Potency APIs Market Size (US$ Bn) Forecast, By Type 9.5. Global High Potency APIs Market Analysis, By Type 9.6. Global High Potency APIs Market Attractiveness Analysis, By Type 10. Global High Potency APIs Market Analysis and Forecast, By Therapeutic Area 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global High Potency APIs Market Value Share Analysis, By Therapeutic Area 10.4. Global High Potency APIs Market Size (US$ Bn) Forecast, By Therapeutic Area 10.5. Global High Potency APIs Market Analysis, By Therapeutic Area 10.6. Global High Potency APIs Market Attractiveness Analysis, By Therapeutic Area 11. Global High Potency APIs Market Analysis, by Region 11.1. Global High Potency APIs Market Value Share Analysis, by Region 11.2. Global High Potency APIs Market Size (US$ Bn) Forecast, by Region 11.3. Global High Potency APIs Market Attractiveness Analysis, by Region 12. North America High Potency APIs Market Analysis 12.1. Key Findings 12.2. North America High Potency APIs Market Overview 12.3. North America High Potency APIs Market Value Share Analysis, By Product 12.4. North America High Potency APIs Market Forecast, By Product 12.4.1. Biotech 12.4.2. Synthetic 12.5. North America High Potency APIs Market Value Share Analysis, By Manufacturer 12.6. North America High Potency APIs Market Forecast, By Manufacturer 12.6.1. Captive 12.6.2. Merchant 12.7. North America High Potency APIs Market Value Share Analysis, By Type 12.8. North America High Potency APIs Market Forecast, By Type 12.8.1. Novel 12.8.2. Innovative 12.8.3. Generic 12.9. North America High Potency APIs Market Value Share Analysis, By Therapeutic Area 12.10. North America High Potency APIs Market Forecast, By Therapeutic Area 12.10.1. Oncology 12.10.2. Glaucoma 12.10.3. Hormonal 12.11. North America High Potency APIs Market Value Share Analysis, by Country 12.12. North America High Potency APIs Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America High Potency APIs Market Analysis, by Country 12.14. U.S. High Potency APIs Market Forecast, By Product 12.14.1. Biotech 12.14.2. Synthetic 12.15. U.S. High Potency APIs Market Forecast, By Manufacturer 12.15.1. Captive 12.15.2. Merchant 12.16. U.S. High Potency APIs Market Forecast, By Type 12.16.1. Novel 12.16.2. Innovative 12.16.3. Generic 12.17. U.S. High Potency APIs Market Forecast, By Therapeutic Area 12.17.1. Oncology 12.17.2. Glaucoma 12.17.3. Hormonal 12.18. Canada High Potency APIs Market Forecast, By Product 12.18.1. Biotech 12.18.2. Synthetic 12.19. Canada High Potency APIs Market Forecast, By Manufacturer 12.19.1. Captive 12.19.2. Merchant 12.20. Canada High Potency APIs Market Forecast, By Type 12.20.1. Novel 12.20.2. Innovative 12.20.3. Generic 12.21. Canada High Potency APIs Market Forecast, By Therapeutic Area 12.21.1. Oncology 12.21.2. Glaucoma 12.21.3. Hormonal 12.22. North America High Potency APIs Market Attractiveness Analysis 12.22.1. By Product 12.22.2. By Manufacturer 12.22.3. By Type 12.22.4. By Therapeutic Area 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe High Potency APIs Market Analysis 13.1. Key Findings 13.2. Europe High Potency APIs Market Overview 13.3. Europe High Potency APIs Market Value Share Analysis, By Product 13.4. Europe High Potency APIs Market Forecast, By Product 13.4.1. Biotech 13.4.2. Synthetic 13.5. Europe High Potency APIs Market Value Share Analysis, By Manufacturer 13.6. Europe High Potency APIs Market Forecast, By Manufacturer 13.6.1. Captive 13.6.2. Merchant 13.7. Europe High Potency APIs Market Value Share Analysis, By Type 13.8. Europe High Potency APIs Market Forecast, By Type 13.8.1. Novel 13.8.2. Innovative 13.8.3. Generic 13.9. Europe High Potency APIs Market Value Share Analysis, By Therapeutic Area 13.10. Europe High Potency APIs Market Forecast, By Therapeutic Area 13.10.1. Oncology 13.10.2. Glaucoma 13.10.3. Hormonal 13.11. Europe High Potency APIs Market Value Share Analysis, by Country 13.12. Europe High Potency APIs Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe High Potency APIs Market Analysis, by Country 13.14. Germany High Potency APIs Market Forecast, By Product 13.14.1. Biotech 13.14.2. Synthetic 13.15. Germany High Potency APIs Market Forecast, By Manufacturer 13.15.1. Captive 13.15.2. Merchant 13.16. Germany High Potency APIs Market Forecast, By Type 13.16.1. Novel 13.16.2. Innovative 13.16.3. Generic 13.17. Germany High Potency APIs Market Forecast, By Therapeutic Area 13.17.1. Oncology 13.17.2. Glaucoma 13.17.3. Hormonal 13.18. U.K. High Potency APIs Market Forecast, By Product 13.18.1. Biotech 13.18.2. Synthetic 13.19. U.K. High Potency APIs Market Forecast, By Manufacturer 13.19.1. Captive 13.19.2. Merchant 13.20. U.K. High Potency APIs Market Forecast, By Type 13.20.1. Novel 13.20.2. Innovative 13.20.3. Generic 13.21. U.K. High Potency APIs Market Forecast, By Therapeutic Area 13.21.1. Oncology 13.21.2. Glaucoma 13.21.3. Hormonal 13.22. France High Potency APIs Market Forecast, By Product 13.22.1. Biotech 13.22.2. Synthetic 13.23. France High Potency APIs Market Forecast, By Manufacturer 13.23.1. Captive 13.23.2. Merchant 13.24. France High Potency APIs Market Forecast, By Type 13.24.1. Novel 13.24.2. Innovative 13.24.3. Generic 13.25. France High Potency APIs Market Forecast, By Therapeutic Area 13.25.1. Oncology 13.25.2. Glaucoma 13.25.3. Hormonal 13.26. Italy High Potency APIs Market Forecast, By Product 13.26.1. Biotech 13.26.2. Synthetic 13.27. Italy High Potency APIs Market Forecast, By Manufacturer 13.27.1. Captive 13.27.2. Merchant 13.28. Italy High Potency APIs Market Forecast, By Type 13.28.1. Novel 13.28.2. Innovative 13.28.3. Generic 13.29. Italy High Potency APIs Market Forecast, By Therapeutic Area 13.29.1. Oncology 13.29.2. Glaucoma 13.29.3. Hormonal 13.30. Spain High Potency APIs Market Forecast, By Product 13.30.1. Biotech 13.30.2. Synthetic 13.31. Spain High Potency APIs Market Forecast, By Manufacturer 13.31.1. Captive 13.31.2. Merchant 13.32. Spain High Potency APIs Market Forecast, By Type 13.32.1. Novel 13.32.2. Innovative 13.32.3. Generic 13.33. Spain High Potency APIs Market Forecast, By Therapeutic Area 13.33.1. Oncology 13.33.2. Glaucoma 13.33.3. Hormonal 13.34. Rest of Europe High Potency APIs Market Forecast, By Product 13.34.1. Biotech 13.34.2. Synthetic 13.35. Rest of Europe High Potency APIs Market Forecast, By Manufacturer 13.35.1. Captive 13.35.2. Merchant 13.36. Rest of Europe High Potency APIs Market Forecast, By Type 13.36.1. Novel 13.36.2. Innovative 13.36.3. Generic 13.37. Rest Of Europe High Potency APIs Market Forecast, By Therapeutic Area 13.37.1. Oncology 13.37.2. Glaucoma 13.37.3. Hormonal 13.38. Europe High Potency APIs Market Attractiveness Analysis 13.38.1. By Product 13.38.2. By Manufacturer 13.38.3. By Type 13.38.4. By Therapeutic Area 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific High Potency APIs Market Analysis 14.1. Key Findings 14.2. Asia Pacific High Potency APIs Market Overview 14.3. Asia Pacific High Potency APIs Market Value Share Analysis, By Product 14.4. Asia Pacific High Potency APIs Market Forecast, By Product 14.4.1. Biotech 14.4.2. Synthetic 14.5. Asia Pacific High Potency APIs Market Value Share Analysis, By Manufacturer 14.6. Asia Pacific High Potency APIs Market Forecast, By Manufacturer 14.6.1. Captive 14.6.2. Merchant 14.7. Asia Pacific High Potency APIs Market Value Share Analysis, By Type 14.8. Asia Pacific High Potency APIs Market Forecast, By Type 14.8.1. Novel 14.8.2. Innovative 14.8.3. Generic 14.9. Asia Pacific High Potency APIs Market Value Share Analysis, By Therapeutic Area 14.10. Asia Pacific High Potency APIs Market Forecast, By Therapeutic Area 14.10.1. Oncology 14.10.2. Glaucoma 14.10.3. Hormonal 14.11. Asia Pacific High Potency APIs Market Value Share Analysis, by Country 14.12. Asia Pacific High Potency APIs Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific High Potency APIs Market Analysis, by Country 14.14. China High Potency APIs Market Forecast, By Product 14.14.1. Biotech 14.14.2. Synthetic 14.15. China High Potency APIs Market Forecast, By Manufacturer 14.15.1. Captive 14.15.2. Merchant 14.16. China High Potency APIs Market Forecast, By Type 14.16.1. Novel 14.16.2. Innovative 14.16.3. Generic 14.17. China High Potency APIs Market Forecast, By Therapeutic Area 14.17.1. Oncology 14.17.2. Glaucoma 14.17.3. Hormonal 14.18. India High Potency APIs Market Forecast, By Product 14.18.1. Biotech 14.18.2. Synthetic 14.19. India High Potency APIs Market Forecast, By Manufacturer 14.19.1. Captive 14.19.2. Merchant 14.20. India High Potency APIs Market Forecast, By Type 14.20.1. Novel 14.20.2. Innovative 14.20.3. Generic 14.21. India High Potency APIs Market Forecast, By Therapeutic Area 14.21.1. Oncology 14.21.2. Glaucoma 14.21.3. Hormonal 14.22. Japan High Potency APIs Market Forecast, By Product 14.22.1. Biotech 14.22.2. Synthetic 14.23. Japan High Potency APIs Market Forecast, By Manufacturer 14.23.1. Captive 14.23.2. Merchant 14.24. Japan High Potency APIs Market Forecast, By Type 14.24.1. Novel 14.24.2. Innovative 14.24.3. Generic 14.25. Japan High Potency APIs Market Forecast, By Therapeutic Area 14.25.1. Oncology 14.25.2. Glaucoma 14.25.3. Hormonal 14.26. ASEAN High Potency APIs Market Forecast, By Product 14.26.1. Biotech 14.26.2. Synthetic 14.27. ASEAN High Potency APIs Market Forecast, By Manufacturer 14.27.1. Captive 14.27.2. Merchant 14.28. ASEAN High Potency APIs Market Forecast, By Type 14.28.1. Novel 14.28.2. Innovative 14.28.3. Generic 14.29. ASEAN High Potency APIs Market Forecast, By Therapeutic Area 14.29.1. Oncology 14.29.2. Glaucoma 14.29.3. Hormonal 14.30. Rest of Asia Pacific High Potency APIs Market Forecast, By Product 14.30.1. Biotech 14.30.2. Synthetic 14.31. Rest of Asia Pacific High Potency APIs Market Forecast, By Manufacturer 14.31.1. Captive 14.31.2. Merchant 14.32. Rest of Asia Pacific High Potency APIs Market Forecast, By Type 14.32.1. Novel 14.32.2. Innovative 14.32.3. Generic 14.33. Rest of Asia Pacific High Potency APIs Market Forecast, By Therapeutic Area 14.33.1. Oncology 14.33.2. Glaucoma 14.33.3. Hormonal 14.34. Asia Pacific High Potency APIs Market Attractiveness Analysis 14.34.1. By Product 14.34.2. By Manufacturer 14.34.3. By Type 14.34.4. By Therapeutic Area 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa High Potency APIs Market Analysis 15.1. Key Findings 15.2. Middle East & Africa High Potency APIs Market Overview 15.3. Middle East & Africa High Potency APIs Market Value Share Analysis, By Product 15.4. Middle East & Africa High Potency APIs Market Forecast, By Product 15.4.1. Biotech 15.4.2. Synthetic 15.5. Middle East & Africa High Potency APIs Market Value Share Analysis, By Manufacturer 15.6. Middle East & Africa High Potency APIs Market Forecast, By Manufacturer 15.6.1. Captive 15.6.2. Merchant 15.7. Middle East & Africa High Potency APIs Market Value Share Analysis, By Type 15.8. Middle East & Africa High Potency APIs Market Forecast, By Type 15.8.1. Novel 15.8.2. Innovative 15.8.3. Generic 15.9. Middle East & Africa High Potency APIs Market Value Share Analysis, By Therapeutic Area 15.10. Middle East & Africa High Potency APIs Market Forecast, By Therapeutic Area 15.10.1. Oncology 15.10.2. Glaucoma 15.10.3. Hormonal 15.11. Middle East & Africa High Potency APIs Market Value Share Analysis, by Country 15.12. Middle East & Africa High Potency APIs Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa High Potency APIs Market Analysis, by Country 15.14. GCC High Potency APIs Market Forecast, By Product 15.14.1. Biotech 15.14.2. Synthetic 15.15. GCC High Potency APIs Market Forecast, By Manufacturer 15.15.1. Captive 15.15.2. Merchant 15.16. GCC High Potency APIs Market Forecast, By Type 15.16.1. Novel 15.16.2. Innovative 15.16.3. Generic 15.17. GCC High Potency APIs Market Forecast, By Therapeutic Area 15.17.1. Oncology 15.17.2. Glaucoma 15.17.3. Hormonal 15.18. South Africa High Potency APIs Market Forecast, By Product 15.18.1. Biotech 15.18.2. Synthetic 15.19. South Africa High Potency APIs Market Forecast, By Manufacturer 15.19.1. Captive 15.19.2. Merchant 15.20. South Africa High Potency APIs Market Forecast, By Type 15.20.1. Novel 15.20.2. Innovative 15.20.3. Generic 15.21. South Africa High Potency APIs Market Forecast, By Therapeutic Area 15.21.1. Oncology 15.21.2. Glaucoma 15.21.3. Hormonal 15.22. Rest of Middle East & Africa High Potency APIs Market Forecast, By Product 15.22.1. Biotech 15.22.2. Synthetic 15.23. Rest of Middle East & Africa High Potency APIs Market Forecast, By Manufacturer 15.23.1. Captive 15.23.2. Merchant 15.24. Rest of Middle East & Africa High Potency APIs Market Forecast, By Type 15.24.1. Novel 15.24.2. Innovative 15.24.3. Generic 15.25. Rest of Middle East & Africa High Potency APIs Market Forecast, By Therapeutic Area 15.25.1. Oncology 15.25.2. Glaucoma 15.25.3. Hormonal 15.26. Middle East & Africa High Potency APIs Market Attractiveness Analysis 15.26.1. By Product 15.26.2. By Manufacturer 15.26.3. By Type 15.26.4. By Therapeutic Area 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America High Potency APIs Market Analysis 16.1. Key Findings 16.2. South America High Potency APIs Market Overview 16.3. South America High Potency APIs Market Value Share Analysis, By Product 16.4. South America High Potency APIs Market Forecast, By Product 16.4.1. Biotech 16.4.2. Synthetic 16.5. South America High Potency APIs Market Value Share Analysis, By Manufacturer 16.6. South America High Potency APIs Market Forecast, By Manufacturer 16.6.1. Captive 16.6.2. Merchant 16.7. South America High Potency APIs Market Value Share Analysis, By Type 16.8. South America High Potency APIs Market Forecast, By Type 16.8.1. Novel 16.8.2. Innovative 16.8.3. Generic 16.9. South America High Potency APIs Market Value Share Analysis, By Therapeutic Area 16.10. South America High Potency APIs Market Forecast, By Therapeutic Area 16.10.1. Oncology 16.10.2. Glaucoma 16.10.3. Hormonal 16.11. South America High Potency APIs Market Value Share Analysis, by Country 16.12. South America High Potency APIs Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America High Potency APIs Market Analysis, by Country 16.14. Brazil High Potency APIs Market Forecast, By Product 16.14.1. Biotech 16.14.2. Synthetic 16.15. Brazil High Potency APIs Market Forecast, By Manufacturer 16.15.1. Captive 16.15.2. Merchant 16.16. Brazil High Potency APIs Market Forecast, By Type 16.16.1. Novel 16.16.2. Innovative 16.16.3. Generic 16.17. Brazil High Potency APIs Market Forecast, By Therapeutic Area 16.17.1. Oncology 16.17.2. Glaucoma 16.17.3. Hormonal 16.18. Mexico High Potency APIs Market Forecast, By Product 16.18.1. Biotech 16.18.2. Synthetic 16.19. Mexico High Potency APIs Market Forecast, By Manufacturer 16.19.1. Captive 16.19.2. Merchant 16.20. Mexico High Potency APIs Market Forecast, By Type 16.20.1. Novel 16.20.2. Innovative 16.20.3. Generic 16.21. Mexico High Potency APIs Market Forecast, By Therapeutic Area 16.21.1. Oncology 16.21.2. Glaucoma 16.21.3. Hormonal 16.22. Rest of South America High Potency APIs Market Forecast, By Product 16.22.1. Biotech 16.22.2. Synthetic 16.23. Rest of South America High Potency APIs Market Forecast, By Manufacturer 16.23.1. Captive 16.23.2. Merchant 16.24. Rest of South America High Potency APIs Market Forecast, By Type 16.24.1. Novel 16.24.2. Innovative 16.24.3. Generic 16.25. Rest of South America High Potency APIs Market Forecast, By Therapeutic Area 16.25.1. Oncology 16.25.2. Glaucoma 16.25.3. Hormonal 16.26. South America High Potency APIs Market Attractiveness Analysis 16.26.1. By Product 16.26.2. By Manufacturer 16.26.3. By Type 16.26.4. By Therapeutic Area 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Mylan, Inc. . 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Company Footprint 17.3.2. Boehringer Ingelheim 17.3.3. Sanofi 17.3.4. AbbVie 17.3.5. Pfizer Inc. 17.3.6. Novartis International AG 17.3.7. Merck & Co. 17.3.8. Cambrex Corporation 17.3.9. Teva Pharmaceutical Industries Ltd. 17.3.10. Eli Lilly and Company 17.3.11. Lonza 17.3.12. AstraZeneca plc 17.3.13. Bristol-Myers Squibb 17.3.14. GlaxoSmithKline plc 18. Primary Key Insights